Mandate

Vinge advises Studentbostäder i Norden AB (publ) in connection with its rights issue and written procedure in relation to its notes

Vinge is advising Studentbostäder i Norden AB (publ), a real estate company whose shares are listed on Nasdaq First North Premier Growth Market, in connection with a fully guaranteed rights issue amounting to a total of SEK 331 million before deduction of transaction costs and the amendments to the terms and conditions of the company’s outstanding green 2021/2024 notes with ISIN SE0015960802 (the “Notes”) by way of a written procedure.

The new shares issued by reason of the rights issue are expected to be admitted to trading on Nasdaq First North Premier Growth Market during week 45, 2023.

The amendments to the terms and conditions of the Notes included, among other things, an extension of the final maturity date to 15 November 2026, an amendment of the interest rate to a fixed PIK interest and a new undertaking for the company to partly amortise the Notes.

Studentbostäder I Norden AB (publ) owns, manages and develops student housing in long term partnerships with municipalities, counties and universities. The company’s shares are listed in Sweden on Nasdaq First North Premier Growth Market under the ticker STUDBO.

Vinge’s team consists of Jesper Schönbeck, Joel Wahlberg, Benjamin Vafaeian, Gabriel Chabo and Alexander Rüdén (Capital Markets and Public M&A), Mikael Ståhl, Lionardo Ojeda, Felix Möller and August Ahlin (Banking and Finance).

Related

Vinge has advised Egetis Therapeutics in connection with a directed share issue

Vinge has advised Egetis Therapeutics AB (publ) (“Egetis Therapeutics”), listed on Nasdaq Stockholm, in connection with a directed share issue whereby Egetis Therapeutics raised proceeds of approximately SEK 183 million before transaction costs.
October 06, 2025

Vinge worked with funds advised by Agilitas on the buy-out of Vivicta (previously Tietoevry Tech Services), including on the issuance of senior secured bonds and on entering into a super senior RCF

Vinge, together with O’Melveny as lead counsel and Avance, worked with funds advised by Agilitas Private Equity LLP (“Agilitas”), the pan-European mid-market private equity firm, in their backing of Vivicta. The buy-out was previously announced on 24 March 2025 and closed on 2 September 2025.
October 03, 2025

Vinge has advised Hansa Biopharma in connection with a directed share issue of approx. SEK 671.5 million

Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of approx. SEK 671.5 million before transaction costs.
October 03, 2025